 |
|
|
|
|
|
|
|
 |
Results for 'Current and Future Therapies for Colorectal Cancer' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Analytical Tool - Analysis of Colorectal Cancer R&D
The Complete Guide
|
September 2005 |
£2635 |
42.5 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5905 |
38 % |
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
|
July 2007 |
£7600 |
37.5 % |
Cancer Drug Discoveries
What the Future Holds
|
August 2005 |
£1995 |
35 % |
Cancer Vaccines
Measuring Market Potential
|
October 2004 |
£1010 |
31.5 % |
Commercial Insight: Targeted Therapy Cancer Brands
High Growth Market Will See Eight New Blockbusters by 2017
|
July 2008 |
£7600 |
27.3 % |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£3400 |
27 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2930 |
26.5 % |
Cancer Therapeutics 2006
Market Dynamics and R&D Trends
|
December 2005 |
£1685 |
26.25 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
26.25 % |
Cancer Therapeutics
Market Insight and R&D Pipeline Analysis
|
August 2008 |
£1460 |
25.9 % |
World Market for Prescription Gastrointestinal Drugs, The
|
July 2006 |
£2355 |
21 % |
World Market for Prescription Respiratory Drugs, The
|
October 2006 |
£2355 |
21 % |
The Worldwide Market for Cancer Diagnostics
3rd Edition
|
March 2008 |
£2690 |
21 % |
Worldwide Market for In Vitro Diagnostic Tests
5th Edition
|
April 2006 |
£2625 |
21 % |
World Market for Psychotherapeutic Drugs, The
|
January 2007 |
£2355 |
21 % |
HIV: A Strategic Analysis of Therapeutic and Testing Markets
|
March 2006 |
£2355 |
21 % |
World Market for Prescription Orthopedic Drugs, The
|
October 2006 |
£2355 |
21 % |
The Impact of the Phase III Pipeline
Future Projections and Market Disruptions
|
March 2006 |
£2355 |
21 % |
World Market for Pain Management Drugs and Devices
2nd Edition
|
December 2006 |
£2355 |
21 % |
World Market for Respiratory Equipment; The
|
November 2005 |
£2355 |
21 % |
Medical and Biological Sensors and Sensor Systems
Markets, Applications, and Competitors Worldwide, 2nd Edition
|
May 2006 |
£2355 |
21 % |
Pharmaceutical Outsourcing Opportunities Post Launch
Contract Manufacturing, and Sales and Marketing,2nd Edition
|
September 2006 |
£2625 |
21 % |
Emerging Cancer Vaccine Market, The
2nd Edition
|
November 2006 |
£2355 |
21 % |
Worldwide Market for Pediatric Drugs; The
2nd Edition
|
November 2005 |
£2355 |
21 % |
Immunomodulators in Cancer Therapy
Emerging Products and Markets
|
August 2004 |
£2355 |
21 % |
Global Market for Adjunctive Therapies in Cancer, The
2nd Edition
|
April 2006 |
£2355 |
21 % |
World Market for Prescription Generic Drugs; The
5th Edition
|
April 2006 |
£2355 |
21 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1545 |
19.95 % |
Colorectal Cancer: Pipeline/Commercial Insight
Shaping the future dynamics of colorectal cancer management
|
October 2006 |
£8000 |
18.9 % |
Commercial Insight: Top 20 Therapy Cancer Brands Key brands set to consolidate advantage as competition intensifies
Key Brands Set to Consolidate Advantage as Competition Intensifies
|
August 2008 |
£7600 |
16.45 % |
Monoclonal Antibody Therapies 2004
Entering A New Competitive Era
|
May 2004 |
£1515 |
16.45 % |
Immunomodulators
Therapeutic Needs, Pipelines & Prospects
|
August 2007 |
£1495 |
15.75 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
14 % |
Angiogenesis Modulators
|
January 2008 |
£1885 |
13.3 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£3265 |
13.3 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
13.3 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2930 |
12.95 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£4400 |
12.95 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4205 |
12.6 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£4400 |
11.55 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2930 |
10.85 % |
What's Hot in Cancer Drug R&D?
|
July 2006 |
£295 |
10.5 % |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
|
October 2006 |
£8000 |
10.5 % |
RNAi
Technologies, Markets and Companies
|
September 2008 |
£2020 |
10.15 % |
Personalized Medicine
scientific & commercial aspects
|
September 2008 |
£2695 |
8.75 % |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£2290 |
8.4 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
8.05 % |
Molecular Diagnostics
Technologies, Markets and Companies
|
September 2008 |
£3030 |
6.3 % |
|
|
|
|
